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The effect of cliphosphonate on crystallization of calciwn oxalate
in vitro. Reliable techniques for the calculation of activity pro-
duct (state of saturation), formation product (limit of meta-
stability) and crystal growth of calcium oxalate were devised.
The activity product at saturation was 2.53 x 10° M2, and was
independent of duration of incubation, solid-to-solution ratio,
pH, calcium concentration or ionic strength. These techniques
were utilized to assess the effect of disodium ethane-l -hydroxy-1,
1-diphosphonate (EHDP) on crystallization of calcium oxalate
in an aqueous salt solution in vitro. EHDP increased the forma-
tion product of calcium oxalate, indicating an inhibition of
nucleation of calcium oxalate. Further, it inhibited the crystal
growth of calcium oxalate.
Effet du diphosphonate sur Ia cristallisation de l'oxalate de cal-
cium in vitro. Des techniques fiables ont été mises au point pour
le calcul du produit de solubilité (état de saturation), du produit
de formation (limite de métastabilité) et de la croissance cristal-
line de l'oxalate de calcium. Le produit de solubilité a saturation
est 2,53 x 10 M2, il est indépendant de la durée de l'incubation,
du rapport solide/solution, du pH, de la concentration du cal-
cium et de la force ionique. Ces techniques ont été utilisées pour
évaluer les effets du disodium ethane-1-hydroxy-l ,1-diphos-
phonate (EHDP) sur la cristallisation de l'oxalate de calcium en
solution aqueuse in vitro. EHDP augmente le produit de forma-
tion de l'oxalate de calcium ce qui indique une inhibition de la
nucleation de l'oxalate de calcium. De surcróit il inhibe la
croissance cristalline de l'oxalate de calcium.
Renal stones of calcium phosphate and calcium
oxalate probably form by nucleation of the crystal
nidus [1,2] followed by the growth of the nidus through
processes of crystal growth [3], epitaxial growth [4] or
crystal aggregation [5]. For stones to develop, the urin-
ary state of supersaturation with respect to constituents
of stones is required, since supersaturation is critical
for nucleation and growth of nidus [1]. Recently,
some insight into these processes has been gained by
the introduction of techniques for the measurement of
activity product (state of saturation) [1, 6], formation
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product (limit of metastability) [3, 7], crystal growth
[3] and crystal aggregation [5, 8].
These techniques have also been utilized to provide
a more rational approach to the treatment of nephroli-
thiasis. The effectiveness of therapy has often been
assessed on the basis of whether the treatment leads to
an inhibition of nucleation or growth of nidus. Thus,
sodium cellulose phosphate reduces the propensity for
nucleation by lowering the urinary state of saturation
with respect to brushite (CaHPO4.2H20) [9, 10], the
probable nidus for calcium phosphate stones and cer-
tain stones of calcium oxalate [1, 11]. Orthophosphate
inhibits nucleation of brushite in urine [12] by stimu-
lating the renal excretion of pyrophosphate, a well-
known inhibitor of calcification [13]. Thiazide diure-
tics usually prevent nucleation of brushite by lowering
the state of saturation and increasing the limit of meta-
stability of brushite [14]. Disodium ethane-1-hydroxy-
1, 1-diphosphonate (EHDP), a synthetic analogue of
pyrophosphate, prevents crystal aggregation of calcium
oxalate [15] and inhibits nucleation and crystal growth
of brushite [3].
in this study, we present techniques for the quanti-
tative assessment of the state of saturation, nucleation
and crystal growth of calcium oxalate. Utilizing these
techniques, we show that EHDP inhibits the nuclea-
tion and crystal growth of calcium oxalate as well.
Methods
Calcium concentration was determined by atomic
absorption spectroscopy. The method for oxalate de-
termination was the same as that of Hodgkinson and
Williams [16], except for the omission of the step
whereby oxalate was precipitated as calcium oxalate.
This omission was justified, since the samples analyzed
did not contain substances which could interfere with
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the determination of oxalate. Administration of caco-
dylate or EHDP did not affect the oxalate assay.
Samples were run in duplicate, and results were accept-
able only if they agreed to within 3 %. The mean of
replicate determinations was used. The recovery of
added oxalate was 100 2 SE%.
Calcium oxalate was prepared as follows. Ten m
solutions of calcium chloride and sodium oxalate were
slowly mixed in equimolar amounts at room temper-
ature by simultaneous introduction of the two solu-
tions at a constant speed of 1 mI/mm. The precipitate
so formed was kept in suspension by means of a mag-
netic stirrer for one week at 6°C. The precipitate was
then separated by centrifugation, washed in distilled
water and in methanol and dried at 95°C for one hour.
The dry preparation was stored at room temperature
before use. It was identified as pure calcium oxalate
monohydrate by X-ray diffraction and by chemical an-
alysis. When viewed in an optical microscope, the
crystals appeared prismatic with approximate edge
length of 1 to 211. Dissolution of crystals in aqueous
solutions of sodium chloride was accompanied by re-
lease into media of equimolar amounts of calcium and
oxalate. After incubation with test solutions, the crys-
tals remained as calcium oxalate monohydrate.
EHDP was slowly introduced to solution under
constant stirring from a stock aqueous solution (0.4mg
of P/ml). Each liter of standard test solutions contained
5 mmoles of sodium cacodylate, varying amounts of
calcium chloride and sodium oxalate and sufficient
sodium chloride to provide an ionic strength of 0.15.
The studies of solubility, nucleation and crystal growth
were conducted at 37°C under constant stirring. The
pH of the solution was 6.0, and ionic strength was 0.15
unless specified otherwise. The ambient fluid was sepa-
rated from the solid phase by filtration in a filter
(Millipore; pore diameter, 0.22 ). Like results were
obtained when the filtrate was obtained in a 0.05 -
diameter filter.
New test tubes (Pyrex), rinsed with distilled water
and dried, were used in the study. There was no evi-
dence for significant fixation of calcium or oxalate to
the tubes.
Activity product of calcium oxalate. The state of
saturation of solutions with respect to calcium oxalate
monohydrate was determined from the activity pro-
duct of Ca + and oxalate ion ([COO]2 or 0x). The
reliability of this technique was tested by determining
the effect of various changes in experimental conditions
on the "solubility" of calcium oxalate at saturation.
Thus, the activity product of calcium oxalate in the
ambient solution was calculated after incubation in an
aqueous solution of varying pH and ionic strength,
using different amounts of calcium oxalate for six
hours to three days. Different amounts of calcium oxa-
late were incubated with test solutions which were "un-
dersaturated" or "supersaturated" with respect to
calcium oxalate. The undersaturated solution con-
tained 0.12 mmoles of calcium and 0.08 mmoles of
oxalate per liter; the supersaturated solution had 0.3
mmoles of calcium and 0.3 mmoles of oxalate per liter.
At various times of incubation, samples of ambient
fluid were obtained and analyzed for calcium and oxa-
late concentration. In experiments which were designed
to assess the effect of pH and ionic strength on solu-
bility, the pH was altered by addition of 0.1 N NaOH
or 0.1 N HC1, and ionic strength was changed by vary-
ing sodium content.
The activity product of calcium oxalate was calcu-
lated from the measured values of calcium and oxalate
according to the following equation:
=aca+ + a= = [Ca++] yca [0x] Yox,
where a is the activity, the brackets [] denote molar
concentration and y represents the activity coefficient.
Since the pK for the reaction of HOOCCOO -°H÷ +
(COO)2 = is 4.29, oxalate was assumed to exist in the
divalent form at the range of urinary pH in this study
(pH greater than 5.1) [17].
Activity coefficients for Ca +÷ and Ox = were calcu-
lated from an extension of the Debye-Huckel limiting
law, which shows dependence of y on ionic strength():
—
Az2\/11
—logy— 1+Bb11 (a)
where z is the valence, b is the effective ionic radius in
Angstroms and A and B are temperature-dependent
constants. The values of Yca + for various ionic
strengths have been presented before [1]. The values of
Vox= were calculated with the values for b, A and B
given by Frankenthel [181 (Table 1).
The ionic concentrations of calcium and oxalate
(Ca + and Ox=) were measured by subtracting the
concentration of soluble complex (CaOx) from the
total, directly measured values of calcium and oxalate
(CaT and OxT).
[Car] = [Ca+ + 1+ [CaOx]
[OxTI = [Ox ] + [CaOx}.
The [CaOx] was obtained from the following:
(b)
(c)
[CaOx] = Kcaox [Ca}[Ox] Vca V0x . (d)
An estimate of [CaOx] was obtained using [Car] and
[OxT] for [Ca J and [0x]. Substitution in equations
b and c yielded estimated values for [Ca +] and [Ox ].
A new value for [CaOx] was calculated from equation
d using estimated values of [Cat ] and [0x]. This
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Table 1. Activity coefficients (y) of Ca and
divalent oxalate ion (Ox)
Ionic strength Vc + + =
0.025 0.564 0.547
0.050 0.478 0.453
0.075 0.430 0.400
0.100 0.396 0.363
0.125 0.367 0.336
0.150 0.353 0.314
0.200 0.323 0.282
0.300 0.287 0.240
iteration was continued until convergence was attained,
usually after three cycles. The value of Kcaox, the
association constant for CaOx, was assumed to be
1537 liters/mole (Nancollas G., personal communica-
tion).
Formation product of calcium oxalate. The effect of
EHDP on the nucleation of calcium oxalate was ex-
amined from the changes in the formation product of
calcium oxalate. The formation product represents the
lowest supersaturated state at which nucleation is
initiated [3, 7]. Thus, an increase in the formation pro-
duct indicates an inhibition of nucleation.
The formation product of calcium oxalate was cal-
culated according to the method based on that for
brushite [3, 7]. To the standard test solutions contain-
ing 1.0 mmoles of calcium/liter, increasing amounts of
oxalate as sodium oxalate were added. The point of
nucleation (formation product) was indicated by the
appearance of a visible precipitate, or by a sudden de-
cline in the activity product of Ca ÷ and Ox. The
formation product was measured at various times for
two days in the absence of, and in the presence of,
EHDP (2 to 8 mg of P/liter).
Crystal growth of calcium oxalate. The method for
estimating the crystal growth is similar to that de-
scribed for brushite [3]. To a solution which was meta-
stably supersaturated with respect to calcium oxalate,
containing 0.3 mmoles of calcium and 0.3 mmoles of
oxalate/liter, a known amount of calcium oxalate was
added. The growth of added calcium oxalate was deter-
mined from the decline in the activity product of Ca ++
and 0x in the ambient fluid. The effect of EHDP was
examined by adding increasing amounts of EHDP (0.5
to 8 mg of P/liter) to the test solution before "seeding"
with calcium oxalate (0.5 mg/ml of solution). The effect
of different amounts of seed was evaluated by adding in-
creasing amounts of calcium oxalate (0.05 mg to 10 ml/
ml of solution) to the test solution containing EHDP
(2 mg of P/mi).
Statistical analysis. Experiments were run in dupli-
cate, except during measurements of formation pro-
duct, in which they were run in triplicate. Results were
acceptable only if the replicate values agreed within
8%. In the figures presented here, each point repre-
sents the mean of replicate experiments. More than
one point for the same experimental condition indi-
cates that studies were repeated on separate days,
utilizing new solutions. Statistical analysis was per-
formed with Student's t test.
Results
Activity product of calcium oxalate. When calcium
oxalate (10 mg/ml solution) was added to the super-
saturated solution, the activity product of Ca ++ and
0x decreased until the steady-state value was reached
at day 1. Thereafter, it did not change significantly
during three days of study. When calcium oxalate was
added to an undersaturated solution, the activity pro-
duct increased until the same steady-state value was
reached at day 1. The results suggest that the solu-
bility of this amount of calcium oxalate reaches the
saturation level in one day. The saturation value
("thermodynamic solubility product") for 32 separate
experiments was 2.53 0.13 x 10 SD M2.
The activity product was also examined for both
supersaturated and undersaturated solutions after dif-
ferent amounts of calcium oxalate (0.5 to 10 mg/mi)
were added. The pH, period of incubation and ionic
strength were kept constant at 6.0, two days and 0.15,
respectively. The values obtained at varying concen-
trations of calcium oxalate (2.51 0.13 x 10 SD M2)
closely approximated the thermodynamic solubility
product.
The effect of pH on the solubility of calcium oxalate
was evaluated by varying pH from 5.10 to 6.95, while
period of incubation, ionic strength and solid/solution
ratio were kept constant at two days, 0.15 and 10 mg/
ml, respectively. Despite changes in pH, the activity
product of 2.48 0.18 x 10 SD M2 approximated the
thermodynamic solubility product. When the final cal-
cium concentrations in solution were varied from 0.1
to 2.0 m by adding increasing amounts of calcium to
the test solution prior to incubation with calcium oxa-
late, the activity product at steady-state of 2.56 x
10 x 0.18 x 10 SD M2 again approximated the ther-
modynamic solubility product.
The effect of ionic strength on the solubility of cal-
cium oxalate is shown in Fig. 1. The ionic strength of
solutions were varied from 0.055 to 0.2, while the
period of incubation, pH and solid/solution ratio were
kept constant at two days, 6.0 and 10, respectively. The
concentration product of Ca + + and Ox increased
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2 days of incubation, pH = 6
Solid/Solution= 10
ConcentrationProd_
linearly with ionic strength. However, the activity pro-
duct was not altered significantly by changes in ionic
strength; the value of 2.54x 10-±Q.15± l0 so M2
approximated the thermodynamic solubility product.
Thus, the same value for activity product of cal-
cium oxalate was reached at steady-state, despite
changes in duration of incubation, solid/solution ratio
pH, calcium concentration or ionic strength.
Effect of EIJDP on the formation product of calcium
oxalate. The formation product, or the minimum activ-
ity product at which spontaneous nucleation of cal-
cium oxalate was initiated, declined with time from the
point of induction by addition of sodium oxalate
(Fig. 2). In the control experiment without EHDP, the
formation product decreased from 4.30 x 10_8 M2 at
15 mm to a steady-state value of 1.58 x 10 M2 at one
day (approximately six-fold saturation). The forma-
tion product was significantly higher in the presence of
EHDP at all time periods (P<0.01). This effect of
EHDP was more pronounced at higher concentration
of EHDP, particularly at early time periods. The
steady-state value for formation product was 2.79 x
50 108 M2 (11-fold saturation) in the presence of 2 mg of
P EHDP/liter, and 3.59 x jQ_8M2 (14-fold saturation)
in the presence of 4 and 8 mg of P EHDP/Iiter.
Effect of EHDP on the crystal growth of calcium
oxalate. The effect of varying amounts of EHDP on the
crystal growth of calcium oxalate (0.5 mg/ml) is shown
in Fig. 3. In the control experiment without EHDP, the
activity product of Ca + + and Ox = declined rapidly to-
ward the thermodynamic solubility product when the
seed of calcium oxalate was added. This decline (or
crystal growth) was inhibited by EHDP. The activity
product in the presence of EHDP was significantly
higher than in the absence of EHDP at all time periods
(P <0.00!). The inhibition of crystal growth of cal-
cium oxalate was more pronounced at higher con-
centrations of EHDP.
The crystal growth of varying amounts of calcium
oxalate (0.05 to 10 mg/ml) at a fixed concentration of
EHDP (2 mg of P/liter) was examined (Fig. 4). In the
absence of EHDP (Fig. 4, top), the activity product of
ambient solution rapidly declined from the metastably
supersaturated state toward the thermodynamic solu-
bility product when calcium oxalate was added. In the
presence of EHDP, the activity product declined
rapidly until it approximated the thermodynamic solu-
bility product when a large amount of calcium oxalate
0
x
+
+
4
3
2
1
•1
Activity
product
20 1
Ionic strength
Fig. 1. The effect of ionic strength on the solubility of calcium
oxalale. The closed circles indicate the solubility expressed as
activity products. The open circles denote concentration pro-
ducts.
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Fig. 3. The effect of EHDP on the crystal growth of calcium
oxalate. To the same metastably supersaturated solution, con-
taining different amounts of EHDP, calcium oxalate (0.5 mg/mi)
was added, and the activity product of Ca + and 0x in am-
bient fluid was measured for three days. The activity product de-
clined to a smaller degree in the presence of EHDP, indicating
inhibition of crystal growth.
Days of incubation
Fig. 2. The effect of EHDP on the formation product of calcium
oxalate. EFIDP increased the formation product of calcium
oxalate.
1 2
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Fig. 4 Dependence of EHDP-induced inhibition of crystal
growth on the concentration of calcium oxalate. Different amounts
of calcium oxalate were incubated with the same metastably
supersaturated solution containing EHDP (2mg of P/liter)
(bottom of figure). In the presence of large amounts of calcium
oxalate (10mg/mi), the activity product approached the thermo-
dynamic solubility product, indicating that this amount of solid
phase overcame the effects of EHDP. However, in the presence
of smaller amounts of calcium oxalate, the activity products
were higher than the saturation value, demonstrating that
EHDP was inhibiting crystal growth of these amounts of calcium
oxalate. In the absence of EHDP, however, the activity product
rapidly declined towards the thermodynamic solubility product
at all concentrations of calcium oxalate (top of figure).
(10 mg/mi) was added (Fig. 4, bottom). Thus, the effect
of EHDP was overcome by an "excess" of calcium
oxalate, allowing for a virtually complete crystal
growth of calcium oxalate. At lower concentrations of
calcium oxalate (0.05 and 0.5 mg/mI), the activity
product did not reach the saturation value, indicating
inhibition of crystal growth of calcium oxalate. At
these concentrations of calcium oxalate, the activity
product was significantly higher in the presence than
in the absence of EHDP(P<O.OO1).
Discussion
Diphosphonate, a synthetic analogue of pyrophos-
phate, is a potent inhibitor of calcification [19]. Since
it is principally excreted in urine, it may be useful in
the control of nephrolithiasis. Thus, EHDP added to
drinking water has been reported to reduce the size of
bladder stones in the rat [20]. In a preliminary study
[211, oral administration of EHDP has been shown to
reduce the frequency of passage of renal stones in
patients with absorptive hypercalciuria [22]. These
effects were observed at an EHDP dosage of 10 to
20 mg/kg/day orally, at which the urinary concentra-
tions may well reach the range of concentrations ex-
amined in this study [21].
The mechanism by which EHDP inhibits the forma-
tion of renal stones of calcium phosphate origin has
been partly appreciated. In an earlier study [3], EHDP
was shown to prevent nucleation and crystal growth of
brushite, the probably nidus for calcium phosphate
stones. Similar understanding for the prevention of
calcium oxalate stone formation has now been realized
with this study of calcium oxalate crystallization.
First, EHDP increased the formation product of
calcium oxalate. The point of spontaneous nucleation
at steady-state increased from 6-fold saturation to as
high as 14-fold saturation in the presence of EHDP.
The formation product was raised by EHDP at all
time periods (from the point of induction). The results
differ from those of Robertson [23], who found that
the formation product of calcium phosphate, measured
at early time periods, was not modified by EHDP.
Second, EHDP inhibited the crystal growth of cal-
cium oxalate. The total amount of calcium oxalate
which crystallized out of solution after seeding was
significantly lower in the presence of EHDP. However,
EHDP was less effective in preventing the crystal
growth of calcium oxalate than that of brushite. EHDP
(8 mg of P/liter) partially inhibited the growth of cal-
cium oxalate (0.5 mg/mi), whereas it completely pre-
vented the growth of the same amount of brushite [3].
This discrepancy probably reflects the fact that our
preparation of calcium oxalate had a smaller crystal-
lite size and, hence, larger surface area for given weight
than brushite.
It should be emphasized that these studies of calcium
oxalate crystallization were based on the determination
of activity product of Ca ÷ ÷ and Ox . The activity
product was determined from the "ionic", and not the
total, concentrations of these ions. By calculating the
concentration of the soluble complex, [CaOx], the
ionic concentrations were obtained as the difference
between total concentrations and [CaOx]. However, in
the conditions of our study, the [CaOx] represented
only a small fraction of total concentrations. Thus, the
activity product, calculated from ionic concentrations,
was lower than that calculated from total concentra-
tions of calcium and oxalate, by less than 25%.
2 mg ofF EHDP/liter
o 0.05 mg of Ca oxalate ml
A 0.5 mg of Ca oxalate/ml
10 mg of Ca oxalate/ml
1 2
Days of incubation
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Although CaEHDP, the soluble complex between
calcium and EHDP, may have formed, we did not
account for such complex formation in our calculation
of the activity product, mainly because of marked dis-
crepancies in the reported values for the association
constant of CaEHDP [24, 25]. However, it is unlikely
that the failure to account for this complex has
seriously affected the conclusions reached. Since studies
were performed at pH 6 and at ionic strength of 0.15,
approximately 14% of EHDP would be expected to be
dissociated as the divalent form [1]. Thus, the maxi-
mum amount of EHDP available for complexation,
calculated for the highest concentration of EHDP used
of 8 mg of P/liter, is 0.018 MM. Even wheh it is assumed
that all of EHDP participates in complex formation,
EHDP would have complexed only 1.8% of calcium
in the formation product studies and less than 9% of
calcium in the crystal growth studies.
Our value for the thermodynamic solubility product
of 2.53 x 10 M2 differed slightly from the reported
value of 1.7 x 10 M2 [6]. However, the validity of our
calculation was supported by the fact that the activity
product at saturation was independent of changes in
duration of incubation, solid/solution ratio, pH, cal-
cium concentration or ionic strength. By utilizing activ-
ity product calculations, it was possible to quantitate
the nucleation and the crystal growth of calcium oxa-
late much more precisely than has been possible pre-
viously [24, 25]. Unfortunately, these studies were per-
formed with calcium oxalate monohydrate rather than
with calcium oxalate dihydrate, even though the latter
compound is a frequent constituent of renal calculi.
We were unable to obtain a pure preparation of cal-
cium oxalate dihydrate.
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